12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Probuphine buprenorphine regulatory update

Titan received a complete response letter from FDA for an NDA for Probuphine buprenorphine to treat opioid dependence. According to the company, the agency requested additional data to support Probuphine's efficacy, including the effects of higher doses of Probuphine. The...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >